Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Matsumoto, NaganoFounded 19461,297 employeesWebsite
A research-driven pharmaceutical company headquartered in Matsumoto, Nagano. It focuses on areas including kidney and urological diseases and rare disorders, developing distinctive medicines to address unmet medical needs.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Products and Services | 80% | ¥78.0B | ¥-4.5B | -5.8% |
| Information Services | 15% | ¥14.2B | ¥1.1B | 7.7% |
| Construction and Facility Maintenance | 4% | ¥4.3B | ¥595M | 13.7% |
| Goods and Supplies Sales | 1% | ¥886M | ¥136M | 15.3% |
Close (Oct 30, 2026)
¥3,805-4.2% (1Y)
Kissei -4.2% over 1Y, 17.5pt below the industry average (23 companies, +13.3%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥97.4B | ¥-2.9B | ¥13.8B | ¥275.1B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
